🏃 Physical Activity Trajectories and Mortality: A Meta-Analysis
A systematic review and meta-analysis of 85 prospective studies, examining the long-term impact of physical activity (PA) patterns throughout adulthood on mortality. The authors aimed to understand how consistent, increasing, or decreasing PA levels are associated with all-cause, cardiovascular disease (CVD), and cancer mortality. The findings indicate that maintaining or increasing PA significantly reduces the risk of all-cause and CVD mortality, with benefits […]
Add Testosterone Booster to the List of Uses for Ozempic
It seems like Ozempic and its GLP-1 brethren Wegovy and Mounjaro are prescription Swiss Army knives that can do a little bit of everything, from melting pounds to keeping type II diabetes under control, along with several other benefits (and, to be fair, some downsides that extend beyond nausea, like blindness). It looks like we […]
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a cornerstone in the treatment of diabetes and obesity and have emerged as a promising option for other metabolic disorders, including hepatic steatosis. Recent evidence highlights the direct and indirect anti-inflammatory properties of GLP-1, suggesting a potential additional therapeutic strategy for patients with inflammatory bowel disease (IBD). However, […]
New Variations on GLP-1–Receptor Agonists are Coming
Randomized trials of not-yet-approved agents highlight once-monthly injection, a new oral option, and drug combination.
Microdosing GLP-1 for Weight Loss: What You Need to Know + 5 Natural Alternatives
Continue reading on Medium »
WeightWatchers Returns With a Plan for the New GLP-1 World
Post Content
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
TUESDAY, July 15, 2025 — For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study published online July 9 in Diabetes, Obesity and…
ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
TUESDAY, July 15, 2025 — In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss outcomes, according to a study presented at ENDO 2025, the annual…
Diabetes patients on Ozempic-like drugs more likely to develop gastroesophageal reflux disease
A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors on the risk for gastroesophageal reflux disease (GERD) and its complications in patients with type 2 diabetes.
Weight-loss wonder drug Mounjaro/Zepbound shrinks breast cancer tumors
A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors. University of Michigan researchers found mice lost about 20 % body weight and adipose tissue while their tumors shrank in tandem, hinting that the blockbuster […]